Filing Details
- Accession Number:
- 0000899243-19-023315
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-09-11 16:05:27
- Reporting Period:
- 2019-09-09
- Accepted Time:
- 2019-09-11 16:05:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1341235 | Aldeyra Therapeutics Inc. | ALDX | Biological Products, (No Disgnostic Substances) (2836) | MA |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1021015 | Richard Douglas | C/O Aldeyra Therapeutics, Inc. 131 Hartwell Avenue, Suite 320 Lexington MA 02421 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-09-09 | 10,000 | $4.91 | 50,000 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-09-10 | 10,000 | $5.09 | 60,000 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.82 to $4.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.